RE:RE:RE:RE:Newsletter out In answer to Thor, the company needs to determine how to administer the vaccine to humans safely and efficaciously. Currently, we only have safety data on bladder instillation.
Note that Study II completion is now approximately 3 years, consistent with treatment of patients in years one and two and one year for demonstrating CR for those yet to be treated. If completion means total N ~ 100, not just the 22--25 for interim, then the pace of recruitment, screening, and successful treatment needs to ramp up significantly. This illustrates the need for the US trial sites to be up and running in the next couple or three quarters.
No firm schedule yet, and all is estimated and subject to change, including costs. That says to me there will be another money raise. If all goes well, the raise will come after the interim is reached with successful results. If all doesn't go well, then....